SFRP5 Enhances Wnt5a Induced-Inflammation in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 03 02 2021
accepted: 01 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 25 2 2023
Statut: epublish

Résumé

Tissue derived fibroblast-like synoviocytes (td-FLS) are key actors in pannus formation and contribute to joint destruction and inflammation during rheumatoid arthritis (RA). Several members of the Wnt family, including Wnt5a, may contribute to RA td-FLS activation and can potentially serve as therapeutic targets. The present work aimed to investigate the expression of Wnt5a signaling elements in RA td-FLS and their potential precursors (fluid derived (fd) FLS and fibrocytes). We also studied the role of Wnt5a in RA td-FLS pro-inflammatory activity and whether the inhibitor SFRP5 could restore Wnt5a-induced synovial dysfunction The levels of Wnt5a, SFRP5, Wnt5a receptors/coreceptors and Wnt5a pro-inflammatory targets were determined in cultured RA td-FLS, fd-FLS and fibrocytes using qPCR under basal conditions. The expression of pro-inflammatory molecules was assessed after RA td-FLS stimulation with Wnt5a and SFRP5 at different time points. Our data showed that td-FLS, fd-FLS and fibrocytes from patients with RA expressed similar levels of Wnt5a and a set of Wnt5a receptors/coreceptors. We also demonstrated that Wnt5a stimulated the expression of the pro-inflammatory targets, especially IL1β, IL8 and IL6 in RA td-FLS. Wnt5a-induced inflammation was enhanced in the presence of SFRP5. Furthermore, Wnt5a alone and in conjunction with SFRP5 inhibited the gene expression of TCF4 and the protein levels of the canonical coreceptor LRP5. Wnt5a pro-inflammatory effect is not inhibited but enhanced by SFRP5 in RA td-FLS. This research highlights the importance of carefully evaluating changes in Wnt5a response in the presence of SFRP5.

Sections du résumé

Background
Tissue derived fibroblast-like synoviocytes (td-FLS) are key actors in pannus formation and contribute to joint destruction and inflammation during rheumatoid arthritis (RA). Several members of the Wnt family, including Wnt5a, may contribute to RA td-FLS activation and can potentially serve as therapeutic targets.
Objective
The present work aimed to investigate the expression of Wnt5a signaling elements in RA td-FLS and their potential precursors (fluid derived (fd) FLS and fibrocytes). We also studied the role of Wnt5a in RA td-FLS pro-inflammatory activity and whether the inhibitor SFRP5 could restore Wnt5a-induced synovial dysfunction
Materials and Methods
The levels of Wnt5a, SFRP5, Wnt5a receptors/coreceptors and Wnt5a pro-inflammatory targets were determined in cultured RA td-FLS, fd-FLS and fibrocytes using qPCR under basal conditions. The expression of pro-inflammatory molecules was assessed after RA td-FLS stimulation with Wnt5a and SFRP5 at different time points.
Results
Our data showed that td-FLS, fd-FLS and fibrocytes from patients with RA expressed similar levels of Wnt5a and a set of Wnt5a receptors/coreceptors. We also demonstrated that Wnt5a stimulated the expression of the pro-inflammatory targets, especially IL1β, IL8 and IL6 in RA td-FLS. Wnt5a-induced inflammation was enhanced in the presence of SFRP5. Furthermore, Wnt5a alone and in conjunction with SFRP5 inhibited the gene expression of TCF4 and the protein levels of the canonical coreceptor LRP5.
Conclusion
Wnt5a pro-inflammatory effect is not inhibited but enhanced by SFRP5 in RA td-FLS. This research highlights the importance of carefully evaluating changes in Wnt5a response in the presence of SFRP5.

Identifiants

pubmed: 34211463
doi: 10.3389/fimmu.2021.663683
pmc: PMC8239419
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Biomarkers 0
Inflammation Mediators 0
SFRP5 protein, human 0
WNT5A protein, human 0
Wnt-5a Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

663683

Informations de copyright

Copyright © 2021 Mahmoud, Kaabachi, Sassi, Mokhtar, Moalla, Ammar, Jemmali, Rekik, Tarhouni, Kallel-Sellami, Cheour and Laadhar.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Autoimmun. 2008 Nov;31(3):219-27
pubmed: 18501558
Science. 2010 Jul 23;329(5990):454-7
pubmed: 20558665
J Leukoc Biol. 2006 Jun;79(6):1242-51
pubmed: 16543402
Rheumatology (Oxford). 2014 Sep;53(9):1704-11
pubmed: 24764263
Arthritis Rheum. 2001 Apr;44(4):772-81
pubmed: 11315916
Eur J Immunol. 2014 May;44(5):1480-90
pubmed: 24643512
J Biol Chem. 2017 Mar 10;292(10):4358
pubmed: 28283587
Cell Signal. 2014 Jan;26(1):94-101
pubmed: 24080158
Development. 2009 Dec;136(24):4083-8
pubmed: 19906850
Clin Exp Rheumatol. 2019 Mar-Apr;37(2):306-309
pubmed: 30620271
PLoS One. 2012;7(4):e34434
pubmed: 22485170
Nat Rev Rheumatol. 2020 Jun;16(6):316-333
pubmed: 32393826
Cytokine. 2012 Oct;60(1):242-8
pubmed: 22763043
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Immunol Invest. 2017 Apr;46(3):314-328
pubmed: 28151034
Ann Rheum Dis. 2010 Sep;69(9):1580-8
pubmed: 20699241
Wiley Interdiscip Rev Syst Biol Med. 2018 Mar 30;:e1422
pubmed: 29600540
J Cell Biol. 2003 Sep 1;162(5):899-908
pubmed: 12952940
J Bone Miner Res. 2012 Mar;27(3):575-85
pubmed: 22162112
EMBO J. 2010 Jan 6;29(1):41-54
pubmed: 19910923
Neurobiol Dis. 2010 May;38(2):148-53
pubmed: 19765659
Exp Mol Med. 2013 Jun 14;45:e27
pubmed: 23764954
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2791-6
pubmed: 10688908
Atherosclerosis. 2020 May;301:15-22
pubmed: 32289618
J Rheumatol. 2005 Feb;32(2):301-6
pubmed: 15693092
Rheumatology (Oxford). 2005 Jun;44(6):708-13
pubmed: 15705634
J Autoimmun. 2016 May;69:38-50
pubmed: 26948996
J Immunol. 2010 Jul 15;185(2):1274-82
pubmed: 20554957
PLoS One. 2015 Mar 16;10(3):e0119709
pubmed: 25774777
FEBS Lett. 2000 Jan 7;465(1):23-7
pubmed: 10620700
PLoS Biol. 2006 Apr;4(4):e115
pubmed: 16602827
Cold Spring Harb Perspect Biol. 2013 Mar 01;5(3):a015081
pubmed: 23085770
Curr Opin Pharmacol. 2013 Jun;13(3):413-9
pubmed: 23562164
Noncoding RNA Res. 2018 Apr 12;3(2):42-53
pubmed: 30159439
Cell. 2017 Jun 1;169(6):985-999
pubmed: 28575679
Angiogenesis. 2018 Nov;21(4):805-821
pubmed: 29845518

Auteurs

Dorra Elhaj Mahmoud (DE)

Immuno-Rheumatology Research Laboratory, Rheumatology Department, La Rabta Hospital, University of Tunis-El Manar, Tunis, Tunisia.

Wajih Kaabachi (W)

Medicine School of Tunis, University of Tunis-El Manar, Tunis, Tunisia.

Nadia Sassi (N)

Immuno-Rheumatology Research Laboratory, Rheumatology Department, La Rabta Hospital, University of Tunis-El Manar, Tunis, Tunisia.

Amel Mokhtar (A)

Immuno-Rheumatology Research Laboratory, Rheumatology Department, La Rabta Hospital, University of Tunis-El Manar, Tunis, Tunisia.

Myriam Moalla (M)

Rheumatology Department, La Rabta Hospital, Tunis, Tunisia.

Lobna Ben Ammar (LB)

Rheumatology Department, La Rabta Hospital, Tunis, Tunisia.

Samia Jemmali (S)

Rheumatology Department, La Rabta Hospital, Tunis, Tunisia.

Sonia Rekik (S)

Rheumatology Department, La Rabta Hospital, Tunis, Tunisia.

Lamjed Tarhouni (L)

Department of Hand and Reconstructive Surgery, Kassab Institute of Traumatic and Orthopedic Surgery, Tunis, Tunisia.

Maryam Kallel-Sellami (M)

Immuno-Rheumatology Research Laboratory, Rheumatology Department, La Rabta Hospital, University of Tunis-El Manar, Tunis, Tunisia.

Elhem Cheour (E)

Immuno-Rheumatology Research Laboratory, Rheumatology Department, La Rabta Hospital, University of Tunis-El Manar, Tunis, Tunisia.

Lilia Laadhar (L)

Immuno-Rheumatology Research Laboratory, Rheumatology Department, La Rabta Hospital, University of Tunis-El Manar, Tunis, Tunisia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH